Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Drugs and Aging

Volumn 18, Issue 6, 2001, Pages 389-396

  Le, W D ^a   Jankovic, J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0035004049     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118060-00001     Document Type: Review

References (63)

1. Neurodegenerative diseases
2. Understanding cell death in Parkinson's disease
3. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
4. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
5. +, a toxin selective to the substantia nigra
6. Covalent crosslinking of neurofilament proteins by oxidized catechols as a potential mechanism of Lewy body formation
7. Oxidative stress and antioxidant therapy in Parkinson's disease
8. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections
9. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): A putative nigral endotoxin of relevance to Parkinson's disease
10. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
11. Therapeutic strategies in Parkinson's disease
12. New and emerging therapies for Parkinson disease
13. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats
14. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
15. Dopamine agonists and neuroprotection in Parkinson's disease
16. 2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
17. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
18. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
19. Apomorphine is a highly free radical scavenger in rat brain mitochondrial fraction
20. Apomorphine protects against MPTP-induced neurotoxicity in mice
21. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
22. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
23. 2 receptors
24. Antioxidant property of pramipexole in neuroprotection
25. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil
26. 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
27. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats
28. Neuroprotection by bromocriptine against 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice
29. 2 receptor agonists protect against ischemia-induced hippocampal neurodegeneration in global cerebral ischaemia
30. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine
31. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
32. 2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
33. 1 agonist in mouse cortical cell cultures
34. 2 and 6-hydroxydopamine
35. Antioxidant properties of bromocriptine, a dopamine agonist
36. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum
37. Scavenging effects of dopamine agonists on nitric oxide radicals
38. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection
39. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain
40. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain
41. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice
42. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures
43. Increase of protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole
44. Alzheimer's disease cybrids replicate β-amyloid abnormalities through cell death pathways
45. Functional roles for dopamine-receptor subtypes
46. 2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo
47. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system
48. L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion
49. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
50. Is levodopa toxic to human substantia nigra?
51. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons
52. Levodopa neurotoxicity: Experimental studies versus clinical relevance
53. Pramipexole enhances Bcl-xl expression in mesencephalic cultures
54. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2
55. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells
56. Inhibition of cell death pathways by S(-) and R(+) pramipexole in pharmacological models of Parkinson's and Alzheimer's disease
57. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
58. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
59. Do dopamine agonists provide neuroprotection?
60. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury
61. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
62. Mutations in the parkin gene causes autosomal recessive juvenile parkinsonism
63. Chronic systemic pesticide exposure produces features of Parkinson's disease